HYHaikun Yang

Haikun Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haikun Yang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Ru Pan

    Department of Gynaecology, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of China

    3 shared publications
  • Hui Rao

    9.796) in NSMP and non-NSMP cases. The proportion of POLE mutant in endometrioid carcinoma was higher than those of other histological types, while the proportion of p53 abnormal was relatively high in high-grade and highly invasive histological types. The proportion of p53 abnormal subtype was relatively high among patients with mixed carcinoma. In addition, the proportions of poor tumor differentiation in the dMMR and p53 abnormal groups were higher than that in the NSMP group

    2 shared publications
  • Yu Luo

    Department of Gynaecology, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of China

    2 shared publications
  • Boming Wu

    Department of Gynaecology, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of China

    1 shared publication
  • Xing Chen

    Data Center, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of China

    1 shared publication
  • Zhengping Zhang

    Department of Gynecology Oncologic Center Meizhou People's Hospital Meizhou China

    1 shared publication

Latest Publications

  • Open Access

    Analysis of the Clinicopathological Characteristics of Different Molecular Subtypes in Endometrial Cancer: A Retrospective Single Center Study

    by Ru Pan, Yu Luo, Boming Wu, Hui Rao, Haikun Yang

    Background: There is significant heterogeneity in the proportion of molecular subtypes of endometrial cancer and its relationship with clinicopathological characteristics among different races and regions. It aims to analyze the differences in the clinicopathological characteristics of different molecular subtypes of endometrial cancer in Eastern Guangdong Province, China. Methods: Five hundred and sixty-three endometrial cancer patients in Meizhou People’s Hospital from January 2018 to August 2024 were collected. The relationship of molecular subtypes (DNA polymerase epsilon (POLE) mutant, mismatch repair deficiency (dMMR), p53 abnormal, and non-specific molecular profile (NSMP)) and clinicopathological characteristics (age, reproductive history, menopausal status, and pathological data covered histological type, tumor differentiation, muscular infiltration, lymphovascular invasion, perineural invasion) were analyzed. Results: The molecular subtypes dMMR, p53 abnormal, POLE mutant, and NSMP were detected in 197 (35.0%), 155 (27.5%), 52 (9.2%), and 159 (28.2%) patients, respectively. There were statistically significant differences in distributions of histological types (p = 0.012, χ2= 14.073), tumor differentiation (p < 0.001, χ2= 16.457), and disease stage (p = 0.019, χ2= 9.796) in NSMP and non-NSMP cases. The proportion of POLE mutant in endometrioid carcinoma was higher than those of other histological types, while the proportion of p53 abnormal was relatively high in high-grade and highly invasive histological types. The proportion of p53 abnormal subtype was relatively high among patients with mixed carcinoma. In addition, the proportions of poor tumor differentiation in the dMMR and p53 abnormal groups were higher than that in the NSMP group. Conclusion: The distribution of molecular subtypes among patients with different histopathological types shows significant differences. The proportion of POLE mutant type in endometrioid carcinoma is higher than that of other histological types, while the proportion of p53 abnormal type is relatively high in high-grade and highly invasive histological types such as serous carcinoma and clear cell carcinoma. It provides valuable reference for guiding the diagnosis and treatment of endometrial cancer by integrating molecular subtypes with clinicopathological characteristics.


  • Open Access

    Revolutionizing diffuse uterine leiomyomatosis treatment: A case report and literature review on “no‐distension” hysteroscopic myomectomy with thoracic tissue forceps

    by Zhengping Zhang, Haikun Yang, Ru Pan

    Diffuse uterine leiomyomatosis (DUL) is a prevalent leiomyoma variant in women of childbearing age, characterized by a uniformly enlarged uterus with numerous interconnected small myomas. Given that most DUL patients are in their reproductive years, treatments that preserve fertility are increasingly vital. This case report introduces an innovative hysteroscopic technique that forgoes uterine distension to remove multiple submucosal fibroids in a single procedure, maintaining endometrial integrity and fertility. A 27‐year‐old single woman experienced prolonged and heavier menstruation. Magnetic resonance imaging (MRI) scans showed an enlarged uterus with several round‐like masses in the uterine wall/submucosa. Addressing the patient's financial limitations and treatment preferences, a groundbreaking hysteroscopic surgery was performed using thoracic tissue forceps, alongside bedside ultrasonography, enabling fibroid excision without uterine distension. In total, 38 uterine fibroids were successfully excised without complications such as uterine perforation or hyponatremia. According to the FIGO classification system: three were type III, nine were type II, 15 were type I, and 11 were type 0. Postoperative follow‐up indicated normalized menstrual cycles, improved hemoglobin levels, and no recurrence of fibroids. A hysteroscopic examination 1 month after surgery revealed no significant fibroids or endometrial thickening. This case report underscores the effectiveness of a novel hysteroscopic surgical approach in treating DUL. This method eliminates the need for multiple staged surgeries and the risks of endometrial damage inherent in traditional techniques. It offers a minimally invasive, fertility‐preserving alternative for young DUL patients, marking a significant advancement in gynecologic surgery.


  • Open Access

    Association Between Germline BRCA1/2 Gene Variants and Clinicopathological Features of Ovarian Cancer

    by Yu Luo, Ru Pan, Hui Rao, Xing Chen, Haikun Yang

    Objective: To investigate the relationship between BRCA1/2 gene mutation and clinicopathological features in ovarian cancer patients, so as to develop precise individualized treatment plan for patients. Methods: Patients diagnosed with ovarian cancer between January 2018 and July 2023 who underwent BRCA1/2 genetic testing were retrospectively analyzed. The clinicopathological characteristics (age, body mass index (BMI), family history of ovarian cancer, pregnancy history, menopause status, tumor size, histopathology, Federation of Gynecology and Obstetrics (FIGO) staging, and ascites) of non-carriers and BRCA1/2 variant carriers were compared. Logistic regression analysis was used to explore the relationship between BRCA1/2 variants and clinicopathological characteristics of ovarian cancer. Results: A total of 284 ovarian cancer patients were collected, and the subjects were divided into two groups, 197 non-carriers and 87 BRCA1/2 variants carriers. The proportion of serous ovarian carcinoma in BRCA1/2 variant carriers is higher than that in non-BRCA variant carriers (78.2% vs 60.9%, p=0.015). There were 51 patients with BRCA pathogenic or likely pathogenic variant, 22 patients with BRCA likely benign variant, and 14 patients with BRCA variants of uncertain significance (VUS). The proportion of serous ovarian carcinoma in patients with BRCA pathogenic/likely pathogenic variant is higher than that in patients with BRCA likely benign variant and BRCA VUS (94.1% vs 50.0% and 64.3%. p< 0.001). There were no statistically significant differences in BMI, family history of ovarian cancer, pregnancy history, menopause status, maximum diameter of the tumor lesion, FIGO stage, and ascites among patients with different grades of variants. Multivariate logistic regression analysis showed that serous ovarian carcinoma was related to BRCA mutation (Serous carcinoma vs non-serous carcinoma: OR 2.145, 95% CI: 1.044– 4.407) (p=0.038). Conclusion: Patients with BRCA1 variant develop ovarian cancer at a younger age than those with the BRCA2 variant. The proportion of FIGO stage III–IV in patients with BRCA pathogenic + likely pathogenic variant was significantly higher than those in patients with other variants. Germline BRCA1/2 variants were most frequently identified in serous ovarian carcinoma patients.